Trials / Completed
CompletedNCT04224116
Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Thoracic Surgery
Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Pulmonary Resection Surgery
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University Tunis El Manar · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Bleeding after thoracic surgery is a major cause of perioperative hemodynamic instability and transfusion requirement, which can lead to a rise of morbidity, mortality and costs. The objective of this study is to evaluate the efficiency of tranexamic acid (TA) in the prevention of perioperative bleeding in thoracic hemorrhagic surgery.
Detailed description
It's a randomized, double-blind, prospective study including patients over the age of 18 years old, programmed for potentially hemorrhagic thoracic surgery, such as pulmonary resection for aspergilloma, pulmonary tuberculosis, pleural decortication, lobectomy with parietectomy or redux. Demographic, clinical, biological data as well as transfusion requirements, blood loss and perioperative complications were identified. Two groups of patients: * TA group: receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act. * Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic acid injection | to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act. |
| DRUG | SSI | Serum Salin isotonic injected |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2019-10-02
- Completion
- 2019-10-02
- First posted
- 2020-01-13
- Last updated
- 2020-01-13
Source: ClinicalTrials.gov record NCT04224116. Inclusion in this directory is not an endorsement.